EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES (EEJBS)
ISSN: 2992-4138 ©EEJBS Publications
Volume 6 Issue 2 2025

Advances in the Pathophysiology and Molecular Diagnostics of Iron Deficiency Anemia: From Biomarkers to Personalized Therapy

Alberta Jeanne N.

School of Applied Health Sciences Kampala International University Uganda

ABSTRACT

Iron deficiency anemia (IDA) remains the most prevalent form of anemia globally, affecting over 1.2 billion people and posing significant public health challenges, particularly among women and children. Traditional diagnostic tools such as serum ferritin and hemoglobin concentration often fall short in accuracy, especially in the context of inflammation. This review explores recent advances in the understanding of IDA pathophysiology, including the pivotal role of hepcidin and the iron regulatory hormone network. Additionally, we examine the evolution of diagnostic strategies from conventional iron indices to novel molecular biomarkers such as soluble transferrin receptor (sTfR), reticulocyte hemoglobin content (CHr), and hepcidin assays. We also discuss emerging technologies, including proteomics, transcriptomics, and the potential of personalized therapy based on genetic and molecular profiles. The integration of molecular diagnostics with individualized therapeutic approaches promises to enhance the precision and effectiveness of IDA management, moving beyond a one-size-fits-all paradigm.

Keywords: Iron deficiency anemia, Hepcidin, Molecular diagnostics, Biomarkers, Personalized therapy

INTRODUCTION

Iron deficiency anemia (IDA) is a prevalent hematological disorder characterized by a reduction in red blood cell count or hemoglobin concentration due to insufficient iron availability [1]. This insufficiency impairs the synthesis of hemoglobin, the oxygen-carrying protein in red blood cells, ultimately leading to decreased oxygen delivery to tissues [1]. The clinical manifestations of IDA include fatigue, pallor, shortness of breath, cognitive impairment, irritability, weakened immunity, and poor physical performance [2]. In children, IDA can result in developmental delays and learning difficulties, while in adults, it may cause reduced work capacity and quality of life [3]. Globally, IDA affects more than 1.2 billion people and is the most common nutritional deficiency, disproportionately impacting women of reproductive age, infants, and individuals in low- and middle-income countries [4]. The condition often arises from inadequate dietary intake, increased physiological demands during pregnancy and growth, chronic blood loss (such as from menstruation or gastrointestinal bleeding), or impaired iron absorption [4]. Although IDA is preventable and treatable, its continued high prevalence suggests that current diagnostic and therapeutic approaches are insufficient, particularly in settings complicated by inflammation or comorbid conditions. In recent years, there has been a growing interest in elucidating the molecular underpinnings of IDA and refining diagnostic techniques beyond conventional laboratory parameters [5]. These advances are paving the way for more precise, individualized treatment regimens that can address the specific pathophysiological mechanisms in each patient. Understanding the molecular control of iron metabolism, particularly the role of key regulatory molecules such as hepcidin, is central to improving both the diagnosis and management of iron deficiency anemia.

2. Pathophysiology of Iron Deficiency Anemia

2.1 Iron Homeostasis and Regulation

Iron homeostasis in the human body is a tightly regulated process, as both deficiency and overload of iron can have harmful consequences. The average adult human body contains about 3 to 4 grams of iron, most of which is found in hemoglobin within red blood cells [6]. Dietary iron is absorbed mainly in the proximal small intestine,

particularly the duodenum, where enterocytes take up iron in its ferrous (Fe^{2+}) form through divalent metal transporter 1 (DMT1) [7]. Once inside the enterocyte, iron can be stored as ferritin or transported into the bloodstream via ferroportin, the only known cellular iron exporter [7].

The activity of ferroportin is regulated by hepcidin, a 25-amino-acid peptide hormone produced primarily in the liver [8]. Hepcidin serves as the master regulator of systemic iron homeostasis. When hepcidin levels are elevated, it binds to ferroportin and causes its internalization and degradation, thereby reducing iron export from enterocytes, hepatocytes, and macrophages into the circulation [8]. Conversely, low hepcidin levels enhance ferroportin activity, promoting increased dietary iron absorption and mobilization from stores [9].

2.2 Role of Hepcidin in Iron Deficiency

Hepcidin plays a dual role in the development and progression of IDA. Under iron-deficient conditions, hepcidin synthesis is downregulated, allowing maximal absorption of dietary iron and mobilization of stored iron to meet the body's needs [9]. However, in the context of inflammation or chronic disease, such as infections, cancer, or autoimmune disorders, pro-inflammatory cytokines, particularly interleukin-6 (IL-6), stimulate hepcidin production irrespective of iron status [10]. This leads to the sequestration of iron in macrophages and reduced intestinal absorption, a condition known as functional iron deficiency [11]. The resulting anemia often mimics true IDA but does not respond well to traditional iron supplementation. The interplay between hepcidin and ferroportin thus lies at the heart of iron regulation, and its dysregulation is central to various forms of anemia, including anemia of chronic disease and mixed anemia [12]. Accurate assessment of hepcidin levels, now possible with specialized assays, may offer clinicians a powerful tool to distinguish between different anemia types and tailor treatment strategies accordingly.

2.3 Genetic and Molecular Insights

In addition to environmental and physiological factors, genetic mutations can significantly influence iron metabolism and contribute to iron deficiency anemia. For instance, mutations in the TMPRSS6 gene, which encodes the enzyme matriptase-2, impair the inhibition of hepcidin production, resulting in elevated hepcidin levels and refractory iron deficiency [13]. Individuals with such mutations often present with iron-refractory iron deficiency anemia (IRIDA), a condition that does not respond to oral iron therapy and requires intravenous iron administration. Other genetic polymorphisms affecting genes involved in iron sensing and transport, such as HFE (associated with hereditary hemochromatosis), TFR2 (transferrin receptor 2), and SLC40A1 (ferroportin), also play a role in modulating iron availability and homeostasis [14]. These findings suggest the potential for developing genotype-based diagnostic and therapeutic approaches. Molecular diagnostics incorporating genetic screening and hepcidin assays could eventually enable clinicians to identify the underlying cause of anemia more accurately and implement individualized treatment plans.

3. Evolution of Diagnostic Tools

3.1 Traditional Biomarkers

The diagnosis of iron deficiency anemia (IDA) has historically depended on conventional hematological and biochemical parameters. These include measurements of hemoglobin concentration, mean corpuscular volume (MCV), serum ferritin, serum iron, total iron-binding capacity (TIBC), and transferrin saturation (TSAT) [15]. Hemoglobin and MCV indicate anemia severity and red blood cell morphology, respectively, while serum ferritin reflects iron storage status [16]. TSAT indicates the proportion of transferrin saturated with iron and serves as a proxy for iron availability in circulation [17].

Despite their widespread use, these markers suffer from significant limitations. Ferritin, an acute-phase reactant, may be elevated in conditions of inflammation, infection, liver disease, and malignancy, even in the presence of true iron deficiency [18]. TSAT and serum iron levels can fluctuate with diurnal variations and dietary intake [19]. As a result, these conventional markers may not reliably distinguish between absolute iron deficiency and functional iron deficiency associated with inflammatory states. Consequently, there has been a growing need for more specific and robust biomarkers capable of reflecting iron status independent of inflammatory confounders.

3.2 Advanced Molecular Biomarkers

In response to these diagnostic challenges, newer biomarkers have emerged that provide deeper insights into iron metabolism and erythropoiesis. One such marker is the soluble transferrin receptor (sTfR), which reflects the demand for iron in the bone marrow and is not significantly affected by inflammation [20]. Elevated sTfR levels typically indicate iron-deficient erythropoiesis and can be used in conjunction with ferritin to improve diagnostic accuracy [21]. Reticulocyte hemoglobin content (CHr) is another valuable parameter, offering real-time information about the iron available for incorporation into newly produced red blood cells [22]. A low CHr value is a sensitive indicator of iron-restricted erythropoiesis and can detect early changes in response to iron therapy [23].

Hepcidin measurement has gained traction as a central tool in assessing iron metabolism. As the key regulator of systemic iron homeostasis, hepcidin levels provide direct information on iron absorption and mobilization [24].

Suppressed hepcidin levels suggest active iron deficiency or increased erythropoietic drive, while elevated levels point to functional deficiency often linked with chronic disease or inflammation [25]. Zinc protoporphyrin (ZPP) levels rise when iron is insufficient for heme synthesis, leading to the incorporation of zinc into protoporphyrin rings instead of iron [26]. Although less specific than hepcidin or CHr, ZPP can serve as a supplementary indicator of iron-deficient erythropoiesis [15].

3.3 Omics and Systems Biology Approaches

Technological advances in omics sciences-particularly proteomics, transcriptomics, and metabolomics, are transforming our understanding of IDA at the molecular level. High-throughput screening methods now enable the profiling of gene expression patterns and protein signatures associated with iron metabolism, erythropoiesis, and inflammation [27]. Transcriptomic studies have revealed differential gene expression in pathways regulating iron transport, oxidative stress, and immune modulation, allowing for stratification of patients based on molecular phenotype [28]. Proteomic analysis of plasma and red blood cell proteins has uncovered novel biomarkers involved in iron trafficking, heme synthesis, and cellular stress responses [29]. These findings have the potential to improve diagnostic discrimination between IDA and anemia of chronic disease. Integrated systems biology approaches that combine clinical, genomic, and proteomic data hold promise for building predictive models that guide diagnosis and treatment decisions with higher precision.

4. Toward Personalized Therapy

4.1 Targeted Iron Supplementation

Personalized treatment of IDA involves tailoring iron therapy to the individual's clinical and molecular profile. Oral iron supplementation, typically in the form of ferrous sulfate, remains the first-line therapy due to its cost-effectiveness and ease of administration [30]. However, gastrointestinal side effects such as constipation, nausea, and epigastric discomfort limit adherence in many patients. Furthermore, absorption of oral iron may be impaired in the presence of high hepcidin levels or gastrointestinal pathology [31]. In such cases, intravenous iron formulations, including ferric carboxymaltose and iron sucrose, offer more efficient and rapid replenishment of iron stores with a favorable safety profile [32]. These formulations are particularly beneficial in patients with inflammatory diseases, chronic kidney disease, or those undergoing surgery. Selection between oral and parenteral iron should therefore consider hepcidin status, absorption potential, urgency of repletion, and patient preference.

4.2 Hepcidin-Guided Therapy

Incorporating hepcidin measurement into clinical decision-making is an emerging paradigm in IDA management [33]. Low hepcidin levels predict a favorable response to oral iron, suggesting that the gastrointestinal tract remains receptive to iron absorption [34]. Conversely, elevated hepcidin levels may indicate reduced absorption potential, guiding the clinician toward parenteral administration or therapeutic strategies to reduce inflammation [35]. Hepcidin-guided therapy is also being explored to prevent iron overload in patients receiving chronic iron supplementation, particularly those with hereditary or inflammatory anemia [36]. Serial hepcidin measurements could eventually serve as a feedback mechanism for dose adjustment and monitoring of therapeutic efficacy.

4.3 Future Directions in Gene-Based Therapy

With growing insights into the genetic regulation of iron metabolism, gene-based interventions are gaining interest. Techniques such as CRISPR/Cas9 genome editing hold potential for correcting mutations in genes such as TMPRSS6, HFE, or SLC40A1 that are implicated in hereditary anemias. Additionally, small interfering RNA (siRNA) therapies targeting hepcidin expression or upstream regulatory pathways may offer novel treatment avenues for refractory or functional IDA. While these technologies remain in preclinical or early clinical phases, their long-term implications for personalized treatment are profound. As molecular diagnostics become more accessible, integrating genomic profiling with biomarker assessment may redefine the clinical management of iron deficiency anemia in the years ahead.

CONCLUSION

Iron deficiency anemia is transitioning from a diagnosis based on simple blood counts to one rooted in molecular precision. Advances in our understanding of iron metabolism and the development of novel biomarkers are paving the way for more accurate diagnosis and personalized treatment strategies. Future integration of omics data, hepcidin assays, and genotype information into clinical workflows may significantly enhance the management of IDA, especially in complex or refractory cases.

REFERENCES

1. Kumar A, Sharma E, Marley A, Samaan MA, Brookes MJ. Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterology. 2022;9(1):e000759. doi:10.1136/bmjgast-2021-000759
2. Warner MJ, Kamran MT. Iron deficiency anemia. StatPearls – NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448065

3. Obeagu, E. I., Nimo, O. M., Bunu, U. M., Ugwu, O. P.C. and Alum, E.U. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med., 2023; (1): 1-7. DOI: http://dx.doi.org/10.22192/ijcrbm.2023.08.01.001.
4. Kumar SB, Arnipalli SR, Mehta P, Carrau S, Ziouzenkova O. Iron deficiency anemia: efficacy and limitations of nutritional and comprehensive mitigation strategies. Nutrients. 2022;14(14):2976. doi:10.3390/nu14142976
5. Liu Q, Jin X, Cheng J, Zhou H, Zhang Y, Dai Y. Advances in the application of molecular diagnostic techniques for the detection of infectious disease pathogens (Review). Molecular Medicine Reports. 2023;27(5). doi:10.3892/mmr.2023.12991
6. Moustarah F, Daley SF. Dietary iron. StatPearls – NCBI Bookshelf. 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540969/
7. Ems T, St Lucia K, Huecker MR. Biochemistry, iron absorption. StatPearls – NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448204/
8. Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu, Simeon Ikechukwu Egba and Obioma Raluchukwu Emeka Obi. Combatting Anaemia in Paediatric Malaria: Effective management strategies Int. J. Curr. Res. Med. Sci. 2023. 9(11): 1-7
9. Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annual Review of Medicine. 2022;74(1):261–77. doi:10.1146/annurev-med-043021-032816
10. Yacoub MF, Ferwiz HF, Said F. Effect of interleukin and hepcidin in anemia of chronic diseases. Anemia. 2020;2020:1–5. doi:10.1155/2020/3041738
11. Jung HL. Absolute versus functional iron deficiency. Clinical and Experimental Pediatrics. 2024;68(2):138–40. doi:10.3345/cep.2023.01732
12. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology. 2011;2011(1):538–42. doi:10.1182/asheducation-2011.1.538
13. Wang CY, Meynard D, Lin HY. The role of TMPRSS6/matriptase-2 in iron regulation and anemia. Frontiers in Pharmacology. 2014;5. doi:10.3389/fphar.2014.00114
14. Hollerer I, Bachmann A, Muckenthaler MU. Pathophysiological consequences and benefits of HFE mutations: 20 years of research. Haematologica. 2017;102(5):809–17. doi:10.3324/haematol.2016.160432
15. Rusch JA, Van Der Westhuizen DJ, Gill RS, Louw VJ. Diagnosing iron deficiency: controversies and novel metrics. Best Practice & Research Clinical Anaesthesiology. 2023;37(4):451–67. doi:10.1016/j.bpa.2023.11.001
16. Christy AL, Manjrekar PA, Babu RP, Hegde A, Rukmini MS. Influence of iron deficiency anemia on hemoglobin A1c levels in diabetic individuals with controlled plasma glucose levels. PubMed. 2014;18(2):88–93. Available from: https://pubmed.ncbi.nlm.nih.gov/24518549
17. Ogun AS, Adeyinka A. Biochemistry, transferrin. StatPearls – NCBI Bookshelf. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532928/
18. Sandnes M, Ulvik RJ, Vorland M, Reikvam H. Hyperferritinemia—A clinical overview. Journal of Clinical Medicine. 2021;10(9):2008. doi:10.3390/jcm10092008
19. Bennett C, Pettikiriarachchi A, McLean ARD, Harding R, Blewitt ME, Seillet C, et al. Serum iron and transferrin saturation variation are circadian regulated and linked to the harmonic circadian oscillations of erythropoiesis and hepatic Tfrc expression in mice. American Journal of Hematology. 2024;99(11):2075–83. doi:10.1002/ajh.27447
20. Hou L, Lu J, Jiang X, Guo X, Ma C, Cheng X. Analytical evaluation of three soluble transferrin receptor measurement systems for diagnosis of iron deficiency anemia: a retrospective study. Journal of Clinical Laboratory Analysis. 2020;34(8). doi:10.1002/jcla.23342
21. Yokus O, Yilmaz B, Albayrak M, Balcik OS, Helvaci MR, Sennaroglu E. The significance of serum transferrin receptor levels in the diagnosis of the coexistence of anemia of chronic disease and iron deficiency anemia. Eurasian Journal of Medicine. 2011;43(1):9–12. doi:10.5152/eajm.2011.02
22. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. American Journal of Hematology. 2007;83(4):307–10. doi:10.1002/ajh.21090
23. Karunarathne P, Kulathilake C, Wijesiriwardena I, Hewageegana A, Marasinghe A. Evaluation of iron status by reticulocyte haemoglobin content (CHr) in chronic kidney disease patients on haemodialysis and erythropoietin. Indian Journal of Hematology and Blood Transfusion. 2021;38(2):359–65. doi:10.1007/s12288-021-01464-3

24. Tussing-Humphreys L, Pustacioglu C, Nemeth E, Braunschweig C. Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: introducing hepcidin. Journal of the Academy of Nutrition and Dietetics. 2012;112(3):391–400. doi:10.1016/j.jada.2011.08.038
25. Karafin MS, Koch KL, Rankin AB, Nischik D, Rahhal G, Simpson P, et al. Erythropoietic drive is the strongest predictor of hepcidin level in adults with sickle cell disease. Blood Cells Molecules and Diseases. 2015;55(4):304–7. doi:10.1016/j.bcmd.2015.07.010
26. Gisslen T, Rao R, Georgieff MK. Anemia, iron supplementation, and the brain. Clinics in Perinatology. 2023;50(4):853–68. doi:10.1016/j.clp.2023.07.009
27. Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nature Reviews Drug Discovery. 2017;16(6):400–23. doi:10.1038/nrd.2016.248
28. Uroko Robert Ikechukwu., Agbafor Amarachi, Uchenna Oluomachi Nancy, Achi Ngozi Kalu, Egba Simeon Ikechukwu**,** Nweje-Anyalowu Paul Chukwuemaka and Ngwu Ogochukwu Rita. Evaluation of Antioxidant Activity of Aqueous Extracts of Palm Friuts *(Elaeis guineensis)* Asian Journal of Biochemistry, 2017; 12: 49-57
29. Voltarelli VA, De Souza RWA, Miyauchi K, Hauser CJ, Otterbein LE. Heme: the lord of the iron ring. Antioxidants. 2023;12(5):1074. doi:10.3390/antiox12051074
30. Lo JO, Benson AE, Martens KL, Hedges MA, McMurry HS, DeLoughery T, et al. The role of oral iron in the treatment of adults with iron deficiency. European Journal of Haematology. 2022;110(2):123–30. doi:10.1111/ejh.13892
31. Stein J, Connor S, Virgin G, Ong DEH, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World Journal of Gastroenterology. 2016;22(35):7908. doi:10.3748/wjg.v22.i35.7908
32. Cançado RD, De Figueiredo PON, Olivato MCA, Chiattone CS. Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia. Revista Brasileira de Hematologia e Hemoterapia. 2011;33(6):439–43. doi:10.5581/1516-8484.20110119
33. Bhandari S, Pereira DIA, Chappell HF, Drakesmith H. Intravenous irons: from basic science to clinical practice. Pharmaceuticals. 2018;11(3):82. doi:10.3390/ph11030082
34. Loveikyte R, Van Den Berg Y, Van Der Meulen-De Jong AE, Vlasveld LT. The role of hepcidin and an oral iron absorption test in identifying the root cause of iron-restricted anemia (Enter-Iron). Acta Haematologica. 2023;147(4):402–12. doi:10.1159/000535275
35. Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation. Current Opinion in Hematology. 2016;23(3):189–97. doi:10.1097/MOH.0000000000000236
36. Sandnes M, Reikvam H. Hepcidin as a therapeutic target in iron overload. Expert Opinion on Therapeutic Targets. 2024;1–8. doi:10.1080/14728222.2024.2443081

Alberta Jeanne N. Advances in the Pathophysiology and Molecular Diagnostics of Iron Deficiency Anemia: From Biomarkers to Personalized Therapy. EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES, 6(2):163-167.